Compare Heron Therapeutics Inc (HRTX) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Kinder Morgan Inc — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Kinder Morgan Inc trades at $32.49 (market cap $71.81B). The key difference: Kinder Morgan Inc is far larger — about 1055.9× Heron Therapeutics Inc's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Kinder Morgan Inc for 150 Days on average.
| HRTX | KMI | |
|---|---|---|
Market Cap | $68.01M | $71.81B |
Volume | 1,891,941 | 16,921,908 |
Sector | Health | Energy |
52-Week High | $1.49 | $34.31 |
52-Week Low | $0.27 | $25.84 |
Typical Hold Time | 35 Days | 150 Days |
Enterprise Value | $174.75M | $103.86B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Kinder Morgan (KMI) trades at $32.49, up 2.11% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.94B in 2025 and net income margin expanding to 19.31%. Recent earnings beats and a $10B project backlog support growth prospects, while analyst consensus targets $37.20 with 47% buy ratings.
KMI presents a compelling investment case with stable fee-based revenues, dividend yield support, and natural gas infrastructure growth. Key risks include energy market volatility and high debt levels ($29.66B long-term). The stock offers upside potential from current levels but requires monitoring of cash flow sustainability and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
